Table of Contents
CURRENT MARKET SIZE
Vaccine Sales breakdown and forecasts
ADDRESSABLE PATIENT POPULATION
PAEDIATRIC VACCINES
ADULT VACCINES
CERVICAL CANCER VACCINES
LUNG CANCER VACCINES
PROSTATE CANCER VACCINES
CURRENT TREATMENTS
VACCINE SALES DRIVERS
VACCINE SALES BREAKERS
FUTURE TREATMENTS
MARKET DYNAMICS - WINNERS & LOSERS
KEY VACCINE LAUNCHES BY 2010
KEY EVALUATION CRITERIA
KEY VACCINE LAUNCHES BY 2010
- Cervarix (GlaxoSmithKline/MedImmune)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management / clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Gardasil (Merck & Co/sanofi pasteur)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management / clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- GVAX (Cell Genesys)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- L-BLP25 (Biomira/Merck KGaA)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of Voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Provenge (Dendreon)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Rotarix (GlaxoSmithKline/Avant Immunotherapeutics)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management and clinical expertise
- Competition within the marketplace/ gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Rotateq (Merck & Co.)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management and clinical expertise
- Competition within the marketplace/ gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Streptorix (GlaxoSmithKline/MedImmune)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Zostavax (Merck & Co.)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management / clinical expertise
- Competition within the marketplace/gaining share of voice
- Filings & Approvals
- Sales forecasts and assumptions
- Competitor Ratio Analysis
COMPETITOR RATIO ANALYSIS SUMMARY
COMPETITOR RATIO ANALYSIS - VACCINES
COMPETITOR RATIO ANALYSIS - COMPANIES
| 
View Cart
